NCRI and Blood Cancer UK used the NCRI Cancer Research Database (CaRD) to analyse the blood cancer funding landscape to understand how funds are distributed across blood cancer types.
Blood cancer data sits on a historically generated backdrop of complexity, with our understanding of these cancers increasing dramatically in recent years. Yet most commonly they are simply reported by a broad grouping of leukaemia, Hodgkin lymphoma, non-Hodgkin lymphoma and myeloma.
Using the National Cancer Research Institute (NCRI) Cancer Research Database (CaRD), in partnership with Blood Cancer UK, the blood cancer funding landscape was assessed at a more granular level. Blood Cancer UK used this data to inform their research strategy.